

Initial Prior Authorization with Logic Elidel

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Elidel	pimecrolimus

Indications

FDA-approved Indications

Elidel (pimecrolimus) Cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable.

Elidel Cream, 1% is not indicated for use in children less than 2 years of age.

Compendial Uses

Psoriasis³ - on the face, genitals, or skin folds.⁶

Atopic Dermatitis for patients under 2 years of age.^{4, 5}

Vitiligo on the head or neck.^{7, 8}

Screen Out Logic

Include Prescription (Rx) and OTC products unless otherwise stated.

If the patient has filled a prescription for at least a 14 day supply of at least one corticosteroid of medium or higher potency within the past 180 days (see examples in Table 1) under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the screen out logic, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

Table 1: Examples of Topical Corticosteroids for Treatment of Atopic Dermatitis ^{2,3,4}

Medium Potency	betamethasone dipropionate lotion, spray 0.05%
Medium Potency	betamethasone valerate cream/lotion 0.1%/foam 0.12%
Medium Potency	clocortolone pivalate cream 0.1%
Medium Potency	desonide lotion, ointment 0.05%
Medium Potency	desoximetasone cream 0.05%
Medium Potency	fluocinolone acetonide cream/ointment/kit 0.025%
Medium Potency	flurandrenolide cream/ointment/lotion 0.05%
Medium Potency	fluticasone propionate cream/lotion 0.05%/ointment 0.005%
Medium Potency	hydrocortisone butyrate cream/lipocream/lotion/ointment/solution 0.1%
Medium Potency	hydrocortisone probutate cream 0.1%
Medium Potency	hydrocortisone valerate cream/ointment 0.2%
Medium Potency	mometasone furoate cream/lotion/solution 0.1%
Medium Potency	prednicarbate cream/ointment 0.1%
Medium Potency	triamcinolone acetonide cream/ointment/lotion/kit 0.1%
Medium Potency	triamcinolone acetonide cream/ointment/lotion 0.025%
Medium Potency	triamcinolone acetonide ointment 0.05%
High Potency	amcinonide cream/ointment/lotion 0.1%
High Potency	betamethasone dipropionate cream/ointment 0.05%
High Potency	betamethasone dipropionate augmented cream/lotion 0.05%
High Potency	betamethasone valerate ointment 0.1%
High Potency	desoximetasone cream/ointment/spray 0.25%/gel/ointment 0.05%
High Potency	diflorasone diacetate cream (emollient base) 0.05% diflorasone cream 0.05%
High Potency	halcinonide cream/ointment 0.1%
High Potency	fluocinonide cream/emulsified cream/ointment/gel/solution 0.05%
High Potency	mometasone furoate ointment 0.1%

High Potency	triamcinolone acetonide aerosol solution 0.147 mg/g
High Potency	triamcinolone acetonide cream/ointment 0.5%
Very High Potency	betamethasone dipropionate augmented ointment/gel 0.05%
Very High Potency	clobetasol propionate cream/ointment/foam/shampoo/gel/lotion/solution/spray 0.05%/cream 0.025%
Very High Potency	diflorasone diacetate ointment 0.05%
Very High Potency	flurandrenolide tape 4mcg/cm ²
Very High Potency	halobetasol propionate cream/ointment/lotion/kit 0.05%
Very High Potency	fluocinonide cream 0.1%

Coverage Criteria

Atopic Dermatitis

Authorization may be granted when the requested drug is being prescribed for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (eczema) when ONE of the following criteria is met:

- The patient is less than 2 years of age.
- The requested drug will be used on sensitive skin areas (e.g., face, genitals, or skin folds).
- The patient has experienced an inadequate treatment response, intolerance, or contraindication to at least ONE first line therapy agent (e.g., medium or higher potency topical corticosteroid).

Psoriasis

Authorization may be granted when the requested drug is being prescribed for psoriasis on the face, genitals, or skin folds.

Vitiligo

Authorization may be granted when the requested drug is being prescribed for vitiligo on the head or neck.

Continuation of Therapy

Atopic Dermatitis

Authorization may be granted when the requested drug is being prescribed for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (eczema) when the following criteria is met:

- The patient has achieved or maintained a positive clinical response as evidenced by improvement [e.g., improvement in or resolution of any of the following signs and symptoms: erythema (redness), edema (swelling), xerosis (dry skin), erosions, excoriations (evidence of scratching), oozing and crusting, lichenification (epidermal thickening), OR pruritus (itching)].

Psoriasis

Authorization may be granted when the requested drug is being prescribed for psoriasis on the face, genitals, or skin folds when the following criteria is met:

- The patient has achieved or maintained a positive clinical response as evidenced by improvement (e.g., clear, or almost clear outcome, patient satisfaction, etc.).

Vitiligo

Authorization may be granted when the requested drug is being prescribed for vitiligo on the head or neck when the following criteria is met:

- The patient has achieved or maintained a positive clinical response as evidenced by improvement (e.g., meaningful repigmentation).

Duration of Approval (DOA)

- 76-D:
 - 2 years of age and older: Initial therapy DOA: 3 months; Continuation of therapy DOA: 36 months
 - Less than 2 years of age: DOA: 3 months

References

1. Elidel [package insert]. Bridgewater, NJ: Bausch Health US, LLC; September 2020.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2025. <https://online.lexi.com>. Accessed February 5, 2025.

Reference number(s)
76-D

3. Micromedex® (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 02/05/2025).
4. Eichenfield L, Tom W, Berger T, et al. Guidelines of Care for the Management of Atopic Dermatitis. Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. J Am Acad Dermatol. 2014 Jul;71:116-32.
5. Sigurgeirsson B, Boznanski A, et al. Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial. Pediatrics. 2015;135(4): 594-606.
6. Elmetts CA, Korman NJ, Prater EF, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb;84(2):432-470.
7. Kubelis-López DE, Zapata-Salazar NA, et al. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021;22(2):797.
8. Eleftheriadou V, Atkar R, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. The British Journal of Dermatology. 2022;186(1):18-29.
9. Eichenfield LF, Tom WL, et. al. Guidelines of Care for the Management of Atopic Dermatitis: Section 1. Diagnosis and Assessment of Atopic Dermatitis. J Am Acad Dermatol 2014; 70:338-51.
10. Sidbury RS, Alikhan A, Berovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023; 89(1): e1-e20.